Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients March 4, 2019 - NYSE Companies 0 » View More News for March 04, 2019
